February 8, 2012
Formula Pharmaceuticals Appoints Dr. Wolfgang Oster as Chairman, Board of Directors
Berwyn, PA – February 8, 2012 – Formula Pharmaceuticals, a privately-held oncology drug development company, today announced the appointment of Wolfgang Oster, MD PhD as Chairman of the Board of Directors. Dr. Oster is the Managing Partner for Life Science at PolyTechnos Venture-Partners and an active Entrepreneur.
“Dr. Oster’s decades of leadership in strategic drug development and business operations has guided numerous life sciences companies in their development of important therapies and their achievement of significant corporate milestones,” said Maurits W. Geerlings, Chief Executive Officer of Formula Pharmaceuticals. “We are delighted to welcome Dr. Oster to our Board of Directors, as Formula Pharmaceuticals will greatly benefit from his leadership, in the capacity of Chairman.”
As an executive, clinical expert and investor, Dr. Oster oversaw the successful developments and market introductions of more than a dozen novel medical products. His successful track record of value creation includes two major trade sales (U.S. BioScience, BiPar), and five IPOs (Devgen, Jerini, Micrus, OncoMethylome, Addex).
“I believe that Formula’s technology holds substantial promise to add a much needed therapeutic modality to current concepts for cancer treatment. I am thrilled by the dedication and determination of the Formula Team to deliver this asset as a future treatment option and as a value for those who share the vision,” remarked Dr Oster.
Dr. Oster is a Board
member of Cappella (Galway, Boston, and Bangalore), Intelligent Medical
Implants (Bonn and Zug), ImmunoGenes (Budapest and Zug), Hemacon
(Düsseldorf and Bangalore), Oncoceutics (Philadelphia), Provid (New
Brunswick), Noblegen (Boston), and Genossis (Philadelphia).
About Formula Pharmaceuticals
Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula’s lead product candidate, FPI-01, is a first-in-class immunotherapeutic in clinical development for the maintenance of first-remission in acute myeloid leukemia (AML) and other cancers. Building upon deep industry expertise in identifying, licensing and developing novel medical approaches, Formula's focus is on accelerating future life-saving cancer therapies.
Founded in late 2009
by Dr. Geerlings and Dr. Giorgio Mosconi, Formula has assembled a
world-class scientific, clinical development and business team well
positioned to maximize the clinical and commercial value of promising
drug candidates through excellence in drug development and strategic
|Copyright 2011 Formula
Page Updated: 07/10/2014 02:46:05 PM